Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00125983 · ClinicalTrials.gov registry record · Phase 2
Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00125983 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 32 participants.
The verdict
NCT00125983, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the drug interactions between a protease inhibitor (PI)-based regimen including lopinavir/ritonavir (LPV/r) and two forms of contraceptive medications in HIV infected women.
Interventions
- DRUG Lopinavir/ritonavir
- DRUG Ortho Novum 1/35
- DRUG Ortho Evra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00125983
The ClinicalTrials.gov registry entry for NCT00125983 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lopinavir/ritonavir is the first listed.
NCT00125983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00125983 about?
NCT00125983 is a clinical study titled "Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women". The purpose of this study is to examine the drug interactions between a protease inhibitor (PI)-based regimen including lopinavir/ritonavir (LPV/r) and two forms of contraceptive medications in HIV infected women.
What is the current status of trial NCT00125983?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00125983?
The interventions under investigation include: Lopinavir/ritonavir (DRUG), Ortho Novum 1/35 (DRUG), Ortho Evra (DRUG).
Who is sponsoring clinical trial NCT00125983?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.